Möchten Sie immer auf dem neuesten Stand bleiben?

Oslo, Norway, 23 May 2024 In relation to the Annual General Meeting in Vistin Pharma ASA (OSE: VISTN), on the 23th of May, the Company's Chair of the Board, Øyvin Brøymer, has received open...

Oslo, Norway, 30 April 2024 Vistin Pharma ASA (OSE: VISTN), please find attached the call for the Annual General Meeting in Vistin Pharma, to be held on 23 May 2024 at 13:00 CEST. A physical...

Oslo, Norway, 24 April 2024 Please find attached the Annual Report for 2023 for Vistin Pharma ASA. There are no material changes in the financial statements compared to the preliminary full...

Oslo, Norway, 24th of April 2024 Vistin Pharma ASA (VISTN) today announces the financial results for the first quarter of 2024. Revenue in the first quarter ended at MNOK 104 compared to...

Oslo, Norway, 16 April 2024 Vistin Pharma ASA will release its first quarter results on Wednesday 24th of April 2024. Vistin Pharma will host a conference call for all shareholders and interested...

Pactum Vekst AS has on March 22, 2024 sold 527 960 shares in Vistin Pharma ASA at a price of NOK 22,10 per share. Espen W. Marcussen, Chair of the board in Pactum Vekst AS, is a primary insider and...

Oslo, Norway, 4 March 2024 Vistin Pharma has aquired a 15% share in CF Pharma Kft. CF Pharma is an API CDMO located in Budapest, Hungary with a broad customer base of recognized international...

The Board of Directors of Vistin Pharma ASA plans to propose to distribute a cash dividend of total NOK 1.00 per share, to be paid partly in June and November, for the accounting year of 2023. The...

Oslo, Norway, 16th of February 2024 Vistin Pharma ASA (Vistin Pharma, OSE: VISTN) today announces the financial results for the fourth quarter of 2023. Vistin delivers another strong quarter with...

Oslo, Norway, 9 February 2024 Vistin Pharma ASA will release its fourth quarter and preliminary 2023 results on Friday 16th of February 2024. Vistin Pharma will host a conference call for all...